SLC7A11与胶质瘤

doi:10.3760/cma.j.cn371439-20220516-00119

摘要/Abstract

摘要：

胶质瘤是成人最常见的原发脑肿瘤，其本质是一种多基因异常疾病。溶质载体家族7成员11（SLC7A11）是编码胱氨酸/谷氨酸反向转运体的核心成分，其表达受转录和翻译层面的调控。SLC7A11通过调节氧化应激与铁死亡介导胶质瘤细胞增殖、侵袭和放化疗抵抗。深入研究SLC7A11将为胶质瘤的治疗提供新的理论依据和治疗靶标。

关键词: 神经胶质瘤, 氧化性应激, 化放疗, SLC7A11

Abstract:

Glioma is the most common primary brain tumor in adults and is essentially a polygenic abnormal disease. Solute carrier family 7 member 11（SLC7A11） is a core component of the cystine/glutamate transporter and its expression is regulated at the transcriptional and translational levels. SLC7A11 mediates glioma cells proliferation， invasion and chemoradiotherapy resistance through regulation of oxidative stress and ferroptosis. Deep study of SLC7A11 will provide new theoretical basis and therapeutic targets for the treatment of gliomas.

Key words: Glioma, Oxidative stress, Chemoradiotherapy, SLC7A11

孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.

Kong Chunyu, Sun Pengfei. SLC7A11 and glioma[J]. Journal of International Oncology, 2022, 49(10): 604-607.

参考文献 38

[1]	Mączyńska J, Raes F, Da Pieve C, et al. Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy[J]. BMC Med, 2022, 20(1) : 16. DOI: 10.1186/s12916-021-02213-z. doi: 10.1186/s12916-021-02213-z
[2]	于学娟, 安宏伟, 孙亚梅, 等. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义[J]. 国际肿瘤学杂志, 2019, 46(12): 718-722. DOI: 10.3760/cma.j.issn.1673-422X.2019.12.003. doi: 10.3760/cma.j.issn.1673-422X.2019.12.003
[3]	Byrne KF, Pal A, Curtin JF, et al. G-protein-coupled receptors as therapeutic targets for glioblastoma[J]. Drug Discov Today, 2021, 26(12): 2858-2870. DOI: 10.1016/j.drudis.2021.07.008. doi: 10.1016/j.drudis.2021.07.008 pmid: 34271165
[4]	Lin W, Wang C, Liu G, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications[J]. Am J Cancer Res, 2020, 10(10): 3106-3126. pmid: 33163260
[5]	Umans RA, Martin J, Harrigan ME, et al. Transcriptional regulation of amino acid transport in glioblastoma multiforme[J]. Cancers (Basel), 2021, 13(24): 6169. DOI: 10.3390/cancers13246169. doi: 10.3390/cancers13246169
[6]	Villalpando-Rodriguez GE, Gibson SB. Reactive oxygen species (ROS) regulates different types of cell death by acting as a rheostat[J]. Oxid Med Cell Longev, 2021, 2021: 9912436. DOI: 10.1155/2021/9912436. doi: 10.1155/2021/9912436
[7]	Patel D, Kharkar PS, Gandhi NS, et al. Novel analogs of sulfasalazine as system x_c^- antiporter inhibitors: insights from the molecular modeling studies[J]. Drug Dev Res, 2019, 80(6): 758-777. DOI: 10.1002/ddr.21557. doi: 10.1002/ddr.21557
[8]	Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4) : 266-282. DOI: 10.1038/s41580-020-00324-8. doi: 10.1038/s41580-020-00324-8
[9]	Dabrowska K, Skowronska K, Popek M, et al. The role of Nrf2 transcription factor and Sp1-Nrf2 protein complex in glutamine transporter SN1 regulation in mouse cortical astrocytes exposed to ammonia[J]. Int J Mol Sci, 2021, 22(20): 11233. DOI: 10.3390/ijms222011233. doi: 10.3390/ijms222011233
[10]	Yu D, Liu Y, Zhou Y, et al. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism[J]. Proc Natl Acad Sci U S A, 2020, 117(18): 9964-9972. DOI: 10.1073/pnas.1913633117. doi: 10.1073/pnas.1913633117 pmid: 32312817
[11]	Fan Z, Wirth AK, Chen D, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis[J]. Oncogenesis, 2017, 6(8): e371. DOI: 10.1038/oncsis.2017.65. doi: 10.1038/oncsis.2017.65
[12]	Tang X, Fu X, Liu Y, et al. Blockade of glutathione metabolism in IDH1-mutated glioma[J]. Mol Cancer Ther, 2020, 19(1): 221-230. DOI: 10.1158/1535-7163.Mct-19-0103. doi: 10.1158/1535-7163.Mct-19-0103
[13]	Chen D, Rauh M, Buchfelder M, et al. The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas[J]. Oncotarget, 2017, 8(31): 51164-51176. DOI: 10.18632/oncotarget.17737. doi: 10.18632/oncotarget.17737 pmid: 28881638
[14]	Wang L, Liu Y, Du T, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc[J]. Cell Death Differ, 2020, 27(2): 662-675. DOI: 10.1038/s41418-019-0380-z. doi: 10.1038/s41418-019-0380-z pmid: 31273299
[15]	Yuan F, Sun Q, Zhang S, et al. The dual role of p62 in ferroptosis of glioblastoma according to p53 status[J]. Cell Biosci, 2022, 12(1): 20. DOI: 10.1186/s13578-022-00764-z. doi: 10.1186/s13578-022-00764-z pmid: 35216629
[16]	Li S, He Y, Chen K, et al. RSL3 drives ferroptosis through NF-κB pathway activation and GPX4 depletion in glioblastoma[J]. Oxid Med Cell Longev, 2021, 2021: 2915019. DOI: 10.1155/2021/2915019. doi: 10.1155/2021/2915019
[17]	Zhao X, Zhou M, Yang Y, et al. The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein[J]. Bioengineered, 2021, 12(2): 12636-12645. DOI: 10.1080/21655979.2021.2011633. doi: 10.1080/21655979.2021.2011633 pmid: 34927544
[18]	Suina K, Tsuchihashi K, Yamasaki J, et al. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-D-aspartate-sensitive glutamate receptor signaling[J]. Cancer Sci, 2018, 109(12): 3874-3882. DOI: 10.1111/cas.13826. doi: 10.1111/cas.13826
[19]	Yamamoto M, Teramoto K, Katoh H. Epidermal growth factor promotes glioblastoma cell death under glucose deprivation via upregulation of xCT (SLC7A11)[J]. Cell Signal, 2021, 78: 109874. DOI: 10.1016/j.cellsig.2020.109874. doi: 10.1016/j.cellsig.2020.109874
[20]	Hua C, Wang X, Liang S, et al. BNIP3 contributes to silibinin-induced DNA double strand breaks in glioma cells via inhibition of mTOR[J]. Biochem Biophys Res Commun, 2022, 589: 1-8. DOI: 10.1016/j.bbrc.2021.11.110. doi: 10.1016/j.bbrc.2021.11.110
[21]	Sorensen MF, Heimisdottir SB, Sorensen MD, et al. High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma[J]. J Neurooncol, 2018, 138(1): 49-53. DOI: 10.1007/s11060-018-2785-9. doi: 10.1007/s11060-018-2785-9
[22]	Chen D, Fan Z, Rauh M, et al. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner[J]. Oncogene, 2017, 36(40): 5593-5608. DOI: 10.1038/onc.2017.146. doi: 10.1038/onc.2017.146 pmid: 28553953
[23]	Wang W, Green M, Choi JE. CD8⁺ T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569(7755): 270-274. DOI: 10.1038/s41586-019-1170-y. doi: 10.1038/s41586-019-1170-y
[24]	Liu X, Zhang Y, Zhuang L, et al. NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation[J]. Genes Dis, 2021, 8(6): 731-745. DOI: 10.1016/j.gendis.2020.11.010. doi: 10.1016/j.gendis.2020.11.010 pmid: 34522704
[25]	Polewski MD, Reveron-Thornton RF, Cherryholmes GA. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties[J]. Stem Cells Dev, 2017, 26(17): 1236-1246. DOI: 10.1089/scd.2017.0123. doi: 10.1089/scd.2017.0123 pmid: 28610554
[26]	Koch K, Hartmann R, Suwala AK, et al. Overexpression of cystine/glutamate antiporter xCT correlates with nutrient flexibility and ZEB1 expression in highly clonogenic glioblastoma stem-like cells (GSCs)[J]. Cancers (Basel), 2021, 13(23): 6001. DOI: 10.3390/cancers13236001. doi: 10.3390/cancers13236001
[27]	Jyotsana N, Ta KT, DelGiorno KE. The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer[J]. Front Oncol, 2022, 12: 858462. DOI: 10.3389/fonc.2022.858462. doi: 10.3389/fonc.2022.858462
[28]	Ye LF, Chaudhary KR, Zandkarimi F, et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers[J]. ACS Chem Biol, 2020, 15(2): 469-484. DOI: 10.1021/acschembio.9b00939. doi: 10.1021/acschembio.9b00939 pmid: 31899616
[29]	Hu N, Hu WH, Zhou SL, et al. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions[J]. Neoplasma, 2021, 68(6): 1147-1156. DOI: 10.4149/neo_2021_210327N410. doi: 10.4149/neo_2021_210327N410 pmid: 34427100
[30]	Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11[J]. Cancer Discov, 2019, 9(12): 1673-1685. DOI: 10.1158/2159-8290.CD-19-0338. doi: 10.1158/2159-8290.CD-19-0338 pmid: 31554642
[31]	Conrad M, Pratt DA. The chemical basis of ferroptosis[J]. Nat Chem Biol, 2019, 15(12): 1137-1147. DOI: 10.1038/s41589-019-0408-1. doi: 10.1038/s41589-019-0408-1 pmid: 31740834
[32]	Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698. DOI: 10.1038/s41586-019-1707-0. doi: 10.1038/s41586-019-1707-0
[33]	Zille M, Kumar A, Kundu N, et al. Ferroptosis in neurons and cancer cells is similar but differentially regulated by histone deacetylase inhibitors[J]. eNeuro, 2019, 6(1): ENEURO.0263-0218.2019. DOI: 10.1523/eneuro.0263-18.2019. doi: 10.1523/eneuro.0263-18.2019
[34]	Alcoreza O, Jagarlamudi S, Savoia A, et al. Sulfasalazine decreases astrogliosis-mediated seizure burden[J]. Epilepsia, 2022, 63(4): 844-854. DOI: 10.1111/epi.17178. doi: 10.1111/epi.17178 pmid: 35132640
[35]	Hsieh CH, Huang YW, Tsai TF. Oral conventional synthetic disease-modifying antirheumatic drugs with antineoplastic potential: a review[J]. Dermatol Ther (Heidelb), 2022, 12(4): 835-860. DOI: 10.1007/s13555-022-00713-1. doi: 10.1007/s13555-022-00713-1
[36]	Yamaguchi I, Yoshimura SH, Katoh H. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11)[J]. J Biol Chem, 2020, 295(20): 6936-6945. DOI: 10.1074/jbc.RA119.012213. doi: 10.1074/jbc.RA119.012213 pmid: 32265299
[37]	Teramoto K, H K. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions[J]. Cell Signal, 2019, 62: 109329. DOI: 10.1016/j.cellsig.2019.05.014. doi: 10.1016/j.cellsig.2019.05.014
[38]	Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT[J]. Mol Cell, 2017, 67(1): 128-138.e127. DOI: 10.1016/j.molcel.2017.05.030. doi: S1097-2765(17)30394-5 pmid: 28648777